SEC Form 4 · accession 0001123292-17-001482
Recro Pharma, Inc. · REPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stewart McCallum
Officer — Chief Medical Officer
Period of report
Sep 28, 2017
Accepted (ET)
Oct 2, 2017 · 6:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001588972
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 28, 2017 | M | 15,000 | — | A | 16,250 | D | |
| Common Stock | Sep 28, 2017 | F | 4,649 | $9.04 | D | 11,601 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On September 28, 2017, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to 15,000 performance-based restricted stock units, which were converted into 15,000 shares of common stock on a one-for-one basis.